Lofexidine Hydrochloride

盐酸洛非西定

Report date: 2023/03/21 10:39:59
NMEFirst In Class

Base Information

Drug NameLofexidine Hydrochloride
Drug Alias NamelofexidinelofexidinalofexidinumBritlofex凯尔丁 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors alpha-2 agonists
TargetsAdrenergic receptors alpha-2
Therapy Area/IndicationsSubstance Withdrawal SyndromeOpioid-Related DisordersSubstance-Related Disorders +[4] 
Global Approved IndicationsSubstance Withdrawal SyndromeOpioid-Related Disorders
Approved Indications in ChinaOpioid-Related Disorders
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date1990/10/12
Country/TerritoryUnited StatesUnited KingdomMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBritannia Pharmaceuticals LtdStada Arzneimittel Ag
China Registration ClassN/A

Develop Information

Active CompaniesBritannia Pharmaceuticals LtdJohns Hopkins UniversityMedical University Of South Carolina +[5] 
Inactive CompaniesNational Institute On Drug AbuseNew York State Psychiatric InstituteUSWM LLC
Active IndicationsSubstance Withdrawal SyndromeOpioid-Related Disorders
Inactive IndicationsSubstance-Related DisordersLiver Failure

Other Information

ATC CodeN07BC04
Related LinksWikipediaDrugBankKEGG